WO1999055331A1 - Utilisation de l'acide alpha-lipoique pour la diminution de l'appetit et/ou la reduction du poids corporel - Google Patents

Utilisation de l'acide alpha-lipoique pour la diminution de l'appetit et/ou la reduction du poids corporel Download PDF

Info

Publication number
WO1999055331A1
WO1999055331A1 PCT/EP1999/002776 EP9902776W WO9955331A1 WO 1999055331 A1 WO1999055331 A1 WO 1999055331A1 EP 9902776 W EP9902776 W EP 9902776W WO 9955331 A1 WO9955331 A1 WO 9955331A1
Authority
WO
WIPO (PCT)
Prior art keywords
lipoic acid
use according
acid
body weight
amines
Prior art date
Application number
PCT/EP1999/002776
Other languages
German (de)
English (en)
Inventor
Joan Dean
Hans Schuhbauer
Joachim Von Seyerl
Ivo Pischel
Stefan Weiss
Original Assignee
Skw Trostberg Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skw Trostberg Aktiengesellschaft filed Critical Skw Trostberg Aktiengesellschaft
Publication of WO1999055331A1 publication Critical patent/WO1999055331A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • alpha lipoic acid to reduce appetite and / or to reduce body weight
  • the present invention relates to the use of ⁇ -lipoic acid to reduce appetite and / or to reduce body weight.
  • BMI body mass index
  • the causes of obesity which are pathological disorders of the physiological energy balance, are manifold: physical peculiarities, eating and exercise behavior, fat storage, ratio of energy intake and energy consumption, genetic and psychological factors, etc.
  • the treatment options of the are accordingly diverse Obesity, if only because, for example, the mechanisms of the body's own fat deposition are just as immune to external influences as genetic factors.
  • a consistent and continued limitation of calorie intake through appropriate dietary measures makes sense from a therapeutic point of view.
  • many patients tend to disregard the reduction diet regulations ("negative compliance"), and therapy concepts that include changing eating habits or psychotherapeutic treatment are generally only partially successful.
  • appetite suppressants so-called anorexigen means, which reduce the craving for food and the appetite and thus reduce the amount of food consumed.
  • anorexigen means, which reduce the craving for food and the appetite and thus reduce the amount of food consumed.
  • anorectics in pharmacologically effective doses show harmful side effects, they partially lose their effectiveness when used over a longer period of time, or they have considerable addictive potential.
  • caffeine (1, 3,7-trimethylxanthine) is associated with increased nervousness and irritability
  • the use of fluoxetine can be too Difficulty sleeping, feeling anxious and suffering from nerves, and dizziness or diarrhea have been observed with fenfluramine (pondimin * , N-ethyl- ⁇ -methyl-3- (trifluoromethyl) phenethylamine).
  • fenfluramine pondimin * , N-ethyl- ⁇ -methyl-3- (trifluoromethyl) phenethylamine.
  • low doses of fenfluramine decreased responsiveness, while ingestion of large amounts caused central excitation effects.
  • Anorexigenic effects have also been observed with some prescription drugs and stimulants (e.g.
  • erythromycin Pediazole * or Ilosone * , a tridecanolide obtained from cultures of Streptomyces erythreus, for example
  • Aminorex Menocil ", 2-amino-5-phenyloxazoline
  • pulmonary hypertension led to the particularly severe side effect of pulmonary hypertension, with occasionally even fatal outcome.
  • the object of the present invention was therefore to provide a new anorectic.
  • An anorectic of natural origin with the broadest possible profile of indications should be used, which does not show any of the harmful side effects that are known from the active ingredients used to date.
  • This object was achieved by using an active ingredient selected from R- ⁇ -lipoic acid, S- ⁇ -lipoic acid, racemic ⁇ -lipoic acid or mixtures or physiologically acceptable salts thereof for the production of an agent for reducing appetite and / or for reducing body weight.
  • - 4 - ⁇ -Lipoic acid thioctic acid, 1, 2-dithiolane-3-pentanoic acid
  • thioctic acid, 1, 2-dithiolane-3-pentanoic acid is a natural product that occurs in low concentrations in plant or animal cells in the form of the R-enantiomer.
  • the ⁇ -lipoic acid originally discovered as a growth factor has a physiological effect in hydrophilic and lipophilic media as a coenzyme for the oxidative decarboxylation of ⁇ -ketocarboxylic acids (e.g. pyruvates) and as an antioxidant. It is also used to regenerate vitamin C, vitamin E, glutathione and coenzyme Q 10.
  • ⁇ -ketocarboxylic acids e.g. pyruvates
  • ⁇ -Lipoic acid is therefore not a pharmaceutical in the usual sense, but is a naturally occurring substrate for primary metabolism.
  • Racemic ⁇ -lipoic acid is approved for the treatment of liver diseases and neuropathies (e.g. diabetic polyneuropathy); their use as an effective inhibitor of the replication of HIV-1 viruses has been discussed (see Klin. Weinschr. 1991, 69 (15), 722-724).
  • the racemate of ⁇ -lipoic acid also has cytoprotective, antiphlogistic and antinociceptive (analgesic) properties, whereby it has been found that in the pure optical isomers of ⁇ -lipoic acid (R- ⁇ -lipoic acid or S- ⁇ -lipoic acid) in In contrast to the racemate, the R enantiomer shows a predominantly antiphlogistic and the S enantiomer shows a predominantly antinociceptive activity profile (cf. EP 812 590 A2).
  • the present invention therefore describes a simple, therapeutically effective and practical method for reducing the feeling of hunger - 5 - and appetite and thus to reduce calorie intake.
  • the use according to the invention is therefore suitable for bringing about a significant weight reduction in overweight, but also in normal weight people. No additional therapeutic or dietary measures are required to achieve this goal; nonetheless, the present use is problem-free and harmless in addition to other forms of treatment, such as, for. B. physical activity, formula diets, psychotherapeutic behavior training, etc. applicable.
  • the ⁇ -lipoic acid according to the invention can be used as optically pure R- ⁇ -lipoic acid, as optically pure S- ⁇ -lipoic acid, as racemic ⁇ -lipoic acid or in the form of a physiologically acceptable salt of one of these optically pure compounds or the racemate .
  • Daily doses between 10 mg and 10.0 g have proven to be particularly effective, this information relating to the free acid form. In order to achieve measurable and above all sustainable success, a period of at least two weeks should be preferred. A time limit for the use according to the invention is not to be observed with a suitable dosage.
  • salts of racemic ⁇ -lipoic acid or salts of optically pure isomers with metals of the 1st and 2nd main groups of the periodic table of elements and elements of III. to VI. Main group of the Periodic Table of the Elements (e.g. selenium) has proven to be particularly suitable.
  • salt formers for the claimed salts of racemic or optically pure ⁇ -lipoic acid are the hydroxides of alkali and alkaline earth metals, ammonium hydroxide, amines of the general formula NR !
  • R 2 R 3 in which the radicals R 1 f R 2 and R 3 independently of one another are hydrogen, C 1-4 alkyl or C 1-4 oxyalkyl, such as monoethanolamine, diethanolamine, 1-amino-propanol or - 6 -
  • alkylenediamines with an alkylene chain of 2 to 6 carbon atoms such as hexamethylene diamine, cyclic amines with 4 to 6 carbon atoms, such as piperidine, piperazine, pyrrolidine or morpholine , basic amino acids such as lysine or arginine, aminocarboxylic acid derivatives, such as. B. creatine, camitin, ornithine, choline or taurine. But also for salts of selected metals in the transition series, such as. B.
  • Racemic ⁇ -lipoic acid, optically pure R- or S- ⁇ -lipoic acid and the salts mentioned are prepared in a known or analogous manner.
  • the claimed administration of the ⁇ -lipoic acid variants takes place in the preferred single doses between 10 mg and 5 g, doses between 50 mg and 2 g being particularly suitable. With regard to the daily dose, the administration of 0.5 to 6 g has proven to be particularly suitable for certain applications. It is completely irrelevant to the success of the use according to the invention whether the pure ⁇ -lipoic acid enantiomers, the racemic mixture or one of the salts described are administered. It is also possible to apply all of these variants in any mixture.
  • the body mass index (BMI) which should preferably be> 25 kg / m 2, has proven to be an advantageous criterion for a clear effect in humans. - 7 -
  • the lipoic acid variants essential to the invention should be administered orally (for example in the form of tablets).
  • Preparations in the form of dietary supplements or additives to so-called dietary supplements have proven to be particularly suitable, since this has a positive effect on compliance.
  • the present use is not restricted to certain dosage forms, which is why any mixtures and combinations, for example with flavorings, but also with other compatible active ingredients, are possible.
  • homogeneously mixed racemic or enantiomerically pure R- or S- ⁇ -lipoic acid or a physiologically active ⁇ -lipoic acid salt with 3 mass equivalents of microcrystalline carboxymethyl cellulose are then added, customary auxiliaries such as. B. magnesium stearate, sorbitol, maltodextrin and / or highly disperse silica gel and finally processes the resulting mixture into tablets of 800 mg each.
  • the equivalent content of ⁇ -lipoic acid per tablet should be 100 mg.
  • ⁇ -lipoic acid according to the invention is preferably suitable as obesity therapy, which can also be carried out over a longer period without problems.
  • Participants in the study were 9 male and 1 1 female subjects between the ages of 33 and 63 years. 7 participants (3m, 4w) had a body mass index (BMI) below 25 kg / m 2 . 13 participants (6m, 7w) had a BMI of more than 25 kg / m 2 and were therefore assigned to first, second or third degree obesity.
  • BMI body mass index
  • the subjects were divided into a therapeutic group (TG) and a control group (KG) of 10 people each.
  • the therapeutic group (TG) received racemic ⁇ -lipoic acid two hours before each meal by oral administration in tablet form with a single dose between 10 mg and 5 g, preferably between 50 mg and 2 g.
  • the active levels thus achieved should then preferably be in the range between 20 and 80 mg per kg of body weight.
  • the total daily dose of ⁇ -lipoic acid should preferably be 0.5 to 6 g.
  • the control group (KG) received an orally administered placebo in tablet form two hours before each meal.
  • Average daily dose per subject 750 mg ⁇ -lipoic acid racemate (therapeutic group) or placebo (control group), administered in single doses of 3 x 250 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'acide R-α-lipoïque ou/et d'acide S-α-lipoïque ou/et d'un de leurs sels physiologiquement biocompatibles en vue de la diminution de l'appétit ou/et de la réduction du poids corporel, en une dose quotidienne préférée de 10 mg à 10 g par rapport à la forme acide libre. Les doses individuelles recommandées sont de 10 mg à 5 g des variantes d'acide α-lipoïque respectives qui sont administrées oralement notamment chez les sujets présentant un indice de masse corporelle > 25 kg/m2. De préférence, l'administration s'effectue sous forme d'un complément nutritif dans le cadre d'un traitement contre l'obésité.
PCT/EP1999/002776 1998-04-25 1999-04-23 Utilisation de l'acide alpha-lipoique pour la diminution de l'appetit et/ou la reduction du poids corporel WO1999055331A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19818563.4 1998-04-25
DE19818563A DE19818563C2 (de) 1998-04-25 1998-04-25 Verwendung von alpha-Liponsäure zur Verringerung des Appetits und/oder zur Körpergewichtsreduzierung

Publications (1)

Publication Number Publication Date
WO1999055331A1 true WO1999055331A1 (fr) 1999-11-04

Family

ID=7865792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/002776 WO1999055331A1 (fr) 1998-04-25 1999-04-23 Utilisation de l'acide alpha-lipoique pour la diminution de l'appetit et/ou la reduction du poids corporel

Country Status (2)

Country Link
DE (1) DE19818563C2 (fr)
WO (1) WO1999055331A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098415A1 (fr) * 2001-06-05 2002-12-12 Joong-Yeol Park Médicament de traitement de l'obésité
US6545039B1 (en) 1999-11-11 2003-04-08 Viatris Gmbh & Co. Kg Facilitated administration of α-lipoic acid or derivatives thereof
WO2004094403A1 (fr) * 2003-04-22 2004-11-04 Laboratorio Chimico Internazionale S.P.A. Sel basique d'acide thioctique avec de la l-carnitine
JP2007508329A (ja) * 2003-10-17 2007-04-05 ダイエット・フォーミュレイションズ・リミテッド 体重減少用サプリメント
WO2008120070A2 (fr) * 2007-03-30 2008-10-09 Aktsionerne Tovarystvo Vidkrytogo Typu «Galychfarm» 2(hydroxyéthyle)triméthylammonium thioctate (choline thioctate) possédant une action hépatoprotectrice, hypoammoniémique et détoxique, procédé de production de cette substance et composition pharmaceutique basée sur ladite substance
JP2012527492A (ja) * 2009-06-24 2012-11-08 セルトリオン ケミカル リサーチ インスティテュート ピペラジンジチオクト酸塩及びこれを含む薬剤学的組成物
WO2014183184A1 (fr) * 2013-05-14 2014-11-20 University Of Prince Edward Island Compositions et méthodes de traitement des maladies et des troubles cardiométaboliques
CN104222518A (zh) * 2008-12-30 2014-12-24 希尔氏宠物营养品公司 用于治疗和预防伴侣动物的与体重相关疾病的组合物和方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US20020076470A1 (en) 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
DE10113974B4 (de) * 2001-03-22 2008-05-29 Alzchem Trostberg Gmbh Verwendung von racemischer und enantiomerenreiner Dihydroliponsäure oder deren Derivate zur Körpergewichtsreduzierung und/oder zur Verringerung des Appetits
DE10137381A1 (de) 2001-07-31 2003-02-13 Viatris Gmbh Neue Modifikationen des Trometamolsalzes der R-Thioctsäure sowie Verfahren zu ihrer Herstellung
WO2006071919A2 (fr) 2004-12-29 2006-07-06 Hill's Pet Nutrition, Inc. Methodes permettant d'inhiber un declin des facultes d'apprentissage et/ou de la memoire chez les animaux
BRPI0613000A2 (pt) 2005-07-14 2012-12-04 Hills Pet Nutrition Inc método para aumentar a longevidade de um animal, artigo de fabricação, kit, e, meio de comunicação de informação acerca de ou instruções para a administração a um animal velho de uma composição
CN101287460B (zh) 2005-08-17 2012-04-25 希尔氏宠物营养品公司 预防和治疗肾病的组合物
AT503329A1 (de) 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
DE202008005023U1 (de) 2008-04-11 2008-07-17 Day-Med-Concept Gmbh Verwendung von α-Liponsäure und Coenzym Q10 zur selektiven Reduktion des visceralen Fettgewebes
US8952052B2 (en) 2008-12-30 2015-02-10 Hill's Pet Nutrition, Inc. Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals
AU2016200420B2 (en) * 2008-12-30 2017-03-02 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4512M (fr) * 1965-05-18 1966-10-17
FR4630M (fr) * 1965-06-09 1966-11-28

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4439477C2 (de) * 1994-11-08 1999-10-21 Asta Medica Ag Verwendung von R,S-(+/-)-alpha-Liponsäure, R-(+)-alpha-Liponäure, S-(-)-alpha-Liponsäure in reduzierter oder oxidierter Form oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung der diabetischen Mikroangiopathie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4512M (fr) * 1965-05-18 1966-10-17
FR4630M (fr) * 1965-06-09 1966-11-28

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HENRIKSEN, ERIK J. ET AL: "Stimulation by.alpha.-lipoic acid of glucose transport activity in skeletal muscle of lean and obese Zucker rats", LIFE SCI. (1997), 61(8), 805-812, XP002113907 *
HENRIKSEN, ERIK J.: "Lipoate effects in an animal model of insulin resistance: the obese Zucker rat", ANTIOXID. HEALTH DIS. (1997), 6(LIPOIC ACID IN HEALTH AND DISEASE), 283-294, XP002113909 *
LOMBARDI D: "Action of thioctic acid and reserpine on weight increase in the chick.", BOLL SOC ITAL BIOL SPER, (1962 JUL 15) 38 610-1., XP002113905 *
RETT K. ET AL: "[Lipoic acid acutely ameliorates insulin sensitivity in obese subjects with type 2 diabetes]. ALPHA-LIPONSAURE (THIOCTSAURE) STEIGERT DIE INSULINEMPFINDLICHKEIT UBERGEWICHTIGER PATIENTEN MIT TYP-II-DIABETES.", DIABETES UND STOFFWECHSEL, (1996) 5/3 SUPPL. (59-63)., XP002113908 *
RETT, K. (1) ET AL: "Effect of acute infusion of thioctic acid on oxidative and non-oxidative metabolism in obese subjects with NIDDM.", DIABETOLOGIA, (1995) VOL. 38, NO. SUPPL. 1, PP. A41. MEETING INFO.: 31ST ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES STOCKHOLM, SWEDEN SEPTEMBER 12-16, 1995, XP002113906 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545039B1 (en) 1999-11-11 2003-04-08 Viatris Gmbh & Co. Kg Facilitated administration of α-lipoic acid or derivatives thereof
WO2002098415A1 (fr) * 2001-06-05 2002-12-12 Joong-Yeol Park Médicament de traitement de l'obésité
KR100427637B1 (ko) * 2001-06-05 2004-04-27 이인규 세포내 에너지 소비 증가제
WO2004094403A1 (fr) * 2003-04-22 2004-11-04 Laboratorio Chimico Internazionale S.P.A. Sel basique d'acide thioctique avec de la l-carnitine
US7235582B2 (en) 2003-04-22 2007-06-26 Laboratorio Chimico Internazionale S.P.A. Basic salt of thioctic acid with L-carnitine
JP2007508329A (ja) * 2003-10-17 2007-04-05 ダイエット・フォーミュレイションズ・リミテッド 体重減少用サプリメント
WO2008120070A2 (fr) * 2007-03-30 2008-10-09 Aktsionerne Tovarystvo Vidkrytogo Typu «Galychfarm» 2(hydroxyéthyle)triméthylammonium thioctate (choline thioctate) possédant une action hépatoprotectrice, hypoammoniémique et détoxique, procédé de production de cette substance et composition pharmaceutique basée sur ladite substance
WO2008120070A3 (fr) * 2007-03-30 2008-12-31 Aktsionerne Tovarystvo Vidkryt 2(hydroxyéthyle)triméthylammonium thioctate (choline thioctate) possédant une action hépatoprotectrice, hypoammoniémique et détoxique, procédé de production de cette substance et composition pharmaceutique basée sur ladite substance
CN104222518A (zh) * 2008-12-30 2014-12-24 希尔氏宠物营养品公司 用于治疗和预防伴侣动物的与体重相关疾病的组合物和方法
JP2012527492A (ja) * 2009-06-24 2012-11-08 セルトリオン ケミカル リサーチ インスティテュート ピペラジンジチオクト酸塩及びこれを含む薬剤学的組成物
WO2014183184A1 (fr) * 2013-05-14 2014-11-20 University Of Prince Edward Island Compositions et méthodes de traitement des maladies et des troubles cardiométaboliques
US10456391B2 (en) 2013-05-14 2019-10-29 University Of Prince Edward Island Compositions and methods for treating cardiometabolic diseases and disorders

Also Published As

Publication number Publication date
DE19818563A1 (de) 1999-10-28
DE19818563C2 (de) 2003-04-17

Similar Documents

Publication Publication Date Title
DE19818563C2 (de) Verwendung von alpha-Liponsäure zur Verringerung des Appetits und/oder zur Körpergewichtsreduzierung
US6136859A (en) Pharmaceutical formulation for treating liver disorders
DE69814834T2 (de) Ernährungszusammensetzung zur verbesserung der zellenenergie
US7335651B2 (en) Compositions incorporating(-)-hydroxycitric acid and related methods for promoting fat oxidation
US20060269617A1 (en) Supplement compositions and method of use for enhancement of insulin sensitivity
AT10974U1 (de) Verwendung von enantiomer-reinem escitalopram
EP0661051A2 (fr) Médicament pour le traitement des altérations de la perfusion
DE3200016C2 (fr)
EP1784177B1 (fr) Formulation pour l-tryptophane comprenant du carbidopa-benserazide
EP1207878B1 (fr) Traitement de la migraine par administration d'acide alpha-lipoique ou de derives de cet acide
WO2005014020A1 (fr) Compositions contenant un extrait de the vert a teneur elevee en cafeine et procedes associes favorisant l'obtention d'un poids adapte
DE10163667B4 (de) Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
DE60207442T2 (de) VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION
EP1909793A2 (fr) Utilisation d'inhibiteurs de phosphodiesterase type 5 pour la prevention et le traitement de maladies ou de troubles, et systemes d'administration associes
DE60028841T2 (de) Verhaltenschemotherapie
EP2731454A1 (fr) Système diététique multi-composants
DE10113974B4 (de) Verwendung von racemischer und enantiomerenreiner Dihydroliponsäure oder deren Derivate zur Körpergewichtsreduzierung und/oder zur Verringerung des Appetits
EP3090638B1 (fr) Complément alimentaire destiné au traitement de carences en vitamine d3
DE202008005023U1 (de) Verwendung von α-Liponsäure und Coenzym Q10 zur selektiven Reduktion des visceralen Fettgewebes
RU2721606C1 (ru) Фармацевтическая композиция для парентерального капельного введения
DE10160485A1 (de) Verwendung von Kreatin und/oder einem seiner physiologisch geeigneten Derivate zur Prävention oder Linderung von nicht krankheitsbedingten Beeinträchtigungen und/oder Störungen der Muskelfunktion
WO1998008521A1 (fr) Preparations vitaminees reduisant la consommation d'oxygene lors d'un effort physique
DE3880579T2 (de) Pharmazeutische zusammensetzungen zur behandlung der verstopfung der luftwege.
US20090326000A1 (en) Resveratrol formulations and methods of use
KR101219541B1 (ko) 간질환제 연질 캡슐 및 그 제조 방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CZ HU JP NO PL US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA